3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Multiple Myeloma
58
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, Follicular
23
Lymphoma
18
Leukemia, Lymphocytic, Chronic, B-Cell
17
Recurrence
16
Lymphoma, Non-Hodgkin
14
Lymphoma, Mantle-Cell
14
Lymphoma, B-Cell, Marginal Zone
12
Lymphoma, B-Cell
10
Neoplasms, Plasma Cell
9
Waldenstrom Macroglobulinemia
6
Hodgkin Disease
6
Neoplasms
5
Leukemia, Myeloid, Acute
5
Burkitt Lymphoma
5
Lymphoma, T-Cell
4
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Large-Cell, Anaplastic
3
Leukemia
3
Hematologic Neoplasms
3
Sezary Syndrome
2
Paraproteinemias
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, Large-Cell, Immunoblastic
2
Interventions
Cetuximab
44
Oxaliplatin
39
Irinotecan
38
Fluorouracil
36
Capecitabine
36
pembrolizumab
35
Leucovorin
35
Bevacizumab
35
Nivolumab
21
Gemcitabine
17
regorafenib
13
Panitumumab
12
IFL protocol
12
Folfox protocol
12
Cyclophosphamide
12
Pemetrexed
11
Cisplatin
11
tislelizumab
9
Paclitaxel
9
HMPL-013
9
Carboplatin
9
130-nm albumin-bound paclitaxel
8
durvalumab
7
Specimen Handling
7
Docetaxel
7
trametinib
6
Trifluridine
6
Ipilimumab
6
Drug Therapy
6
trifluridine tipiracil drug combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Neoplasms
×
Lenalidomide
×
Clear all
NCT01166035
2010-07-20
TEXO
Medical University Innsbruck
Phase 1/2
Unknown
20 enrolled